Raynaud Disease

Categories: Blood diseases, Cardiovascular diseases, Rare diseases, Skin diseases

Aliases & Classifications for Raynaud Disease

MalaCards integrated aliases for Raynaud Disease:

Name: Raynaud Disease 56 12 15 17 71
Raynaud's Disease 12 42
Raynaud Syndrome 36 32
Secondary Raynaud's Phenomenon 71
Cold Fingers, Hereditary 56
Raynaud's Syndrome 12
Raynaud Phenomenon 71
Raynauds Syndrome 54



autosomal dominant


raynaud disease:
Inheritance autosomal dominant inheritance


External Ids:

Disease Ontology 12 DOID:10300
OMIM 56 179600
KEGG 36 H01620
SNOMED-CT 67 195295006
ICD10 32 I73.0
MedGen 41 C0034734
SNOMED-CT via HPO 68 263681008 266261006
UMLS 71 C0034734 C0034735 C1282916

Summaries for Raynaud Disease

MedlinePlus : 42 Raynaud's disease is a rare disorder of the blood vessels, usually in the fingers and toes. It causes the blood vessels to narrow when you are cold or feeling stressed. When this happens, blood can't get to the surface of the skin and the affected areas turn white and blue. When the blood flow returns, the skin turns red and throbs or tingles. In severe cases, loss of blood flow can cause sores or tissue death. Primary Raynaud's happens on its own. The cause is unknown. There is also secondary Raynaud's, which is caused by injuries, other diseases, or certain medicines. People in colder climates are more likely to develop Raynaud's. It is also more common in women, people with a family history, and those over age 30. Treatment for Raynaud's may include drugs to keep the blood vessels open. There are also simple things you can do yourself, such as Soaking hands in warm water at the first sign of an attack Keeping your hands and feet warm in cold weather Avoiding triggers, such as certain medicines and stress NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Raynaud Disease, also known as raynaud's disease, is related to raynaud phenomenon and scleroderma, familial progressive, and has symptoms including fatigue, fever and edema. An important gene associated with Raynaud Disease is CENPB (Centromere Protein B), and among its related pathways/superpathways are cGMP-PKG signaling pathway and Renin secretion. The drugs Cilostazol and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and heart, and related phenotypes are abnormality of the skeletal system and raynaud phenomenon

KEGG : 36 Raynaud syndrome (RS) is characterized by episodic digital ischemia induced by cold or emotional stress. Pathophysiologic mechanisms include temporary vasospasm and fixed digital artery obstruction. Although the underlying pathophysiological mechanism is unclear, alterations in activity of the peripheral adrenoceptor have been implicated, specifically an enhanced smooth muscle contraction due to overexpression or hyperactivity of postsynaptic alpha 2 receptors. RS can occur as an isolated entity, historically referred to as Raynaud disease or now primary RS, or in association with other conditions, most frequently the connective tissue diseases (eg, scleroderma [DS:H01492], systemic lupus erythematosus [DS:H00080], rheumatoid arthritis [DS:H00630], and Sjogren's syndrome [DS:H01502]), often referred to as Raynaud phenomenon or secondary RS. The diagnosis is mainly clinical, based on patient descriptions of skin changes. Therapy has been focused on the use of general vasodilation strategies.

Wikipedia : 74 Raynaud syndrome, also known as Raynaud's phenomenon, is a medical condition in which spasm of arteries... more...

More information from OMIM: 179600

Related Diseases for Raynaud Disease

Diseases related to Raynaud Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 354)
# Related Disease Score Top Affiliating Genes
1 raynaud phenomenon 33.0 PDE5A EDN1 ADRA2C
2 scleroderma, familial progressive 31.0 TOP1 EDN1 CENPB
3 purpura 30.3 CRP CD40LG ACE
4 angina pectoris 30.2 EDN1 CRP ACE
5 peripheral artery disease 30.1 EDN1 CRP ACE
6 intermittent claudication 30.1 CRP CD40LG ACE
7 fibromuscular dysplasia 30.0 AGTR1 ACE
8 parotitis 30.0 TRIM21 CRP CD40LG
9 telangiectasis 29.9 TRIM21 TOP1 SNRNP70 EXOSC10 CENPB
10 late congenital syphilis 29.9 CRP CD40LG
11 atherosclerosis susceptibility 29.9 EDN1 CRP AGTR1 ACE
12 collagen disease 29.9 TRIM21 SNRNP70 CRP CD40LG
13 syphilis 29.9 CRP CD40LG ACE
14 pericarditis 29.8 CRP CD40LG ACE
15 autoimmune disease 29.7 TRIM21 IL1R1 CRP CENPB CD40LG
16 hellp syndrome 29.7 EDN1 CRP CD40LG
17 complex regional pain syndrome 29.7 EDN1 CALCA ACE
18 pulmonary edema 29.7 EDN1 CRP AGTR1 ACE
19 migraine with aura 29.6 EDN1 CALCA ACE
20 fibromyalgia 29.6 HTR3A CRP CALCA
21 behcet syndrome 29.6 IL1R1 CRP CD40LG ACE
22 vascular disease 29.6 EDN1 CRP CD40LG AGTR1 ACE
23 crest syndrome 29.4 TOP1 SNRNP70 EXOSC10 CENPB CD40LG
24 polyneuropathy 29.3 CRP CD40LG CALCA ACE
25 peripheral nervous system disease 29.2 CRP CD40LG CALCA ACE
26 pulmonary hypertension 29.2 PDE5A EDN1 CRP CALCA AGTR1 ACE
27 systemic scleroderma 29.1 TRIM21 TOP1 SNRNP70 EXOSC10 EDN1 CRP
28 connective tissue disease 28.9 TOP1 SNRNP70 EDN1 CRP CENPB CD40LG
29 coronary artery vasospasm 28.8 EDN1 CRP ADRA2C ADRA2B ACE
30 systemic lupus erythematosus 28.7 TRIM21 SNRNP70 IL1R1 CRP CENPB CD40LG
31 migraine with or without aura 1 28.6 PDE5A HTR3A EDN1 CRP CD40LG CALCA
32 diffuse scleroderma 28.6 TRIM21 TOP1 SNRNP70 EXOSC10 EDN1 CENPB
33 diabetes mellitus 28.3 PDE5A IL1R1 EDN1 CRP CD40LG CALCA
34 hypertension, essential 27.1 PDE5A EDN1 CRP CD40LG CALCA AGTR1
35 reynolds syndrome 11.5
36 malignant secondary hypertension 10.5 TRIM21 AGTR1
37 cerebral arteritis 10.5 EDN1 CD40LG
38 subacute cutaneous lupus erythematosus 10.4 TRIM21 ACE
39 cryopyrin-associated periodic syndrome 10.4 IL1R1 CRP
40 histoplasmosis meningitis 10.4 CD40LG ACE
41 chronic thromboembolic pulmonary hypertension 10.4 EDN1 CRP
42 brawny scleritis 10.4 CD40LG ACE
43 granulomatous myositis 10.4 TRIM21 ACE
44 malignant renovascular hypertension 10.4 EDN1 AGTR1
45 posterior urethral valves 10.4 AGTR1 ACE
46 mediastinum teratoma 10.4 CRP ACE
47 hyperglobulinemic purpura 10.4 TRIM21 CD40LG
48 iga nephropathy 1 10.4 AGTR1 ACE
49 conjunctival vascular disease 10.4 TRIM21 TOP1
50 acute dacryoadenitis 10.4 CRP ACE

Graphical network of the top 20 diseases related to Raynaud Disease:

Diseases related to Raynaud Disease

Symptoms & Phenotypes for Raynaud Disease

Human phenotypes related to Raynaud Disease:

# Description HPO Frequency HPO Source Accession
1 abnormality of the skeletal system 31 HP:0000924
2 raynaud phenomenon 31 HP:0030880

Symptoms via clinical synopsis from OMIM:

intermittent attacks of numb and white fingers

Clinical features from OMIM:


UMLS symptoms related to Raynaud Disease:

fatigue, fever, edema, pruritus, nausea and vomiting, abdominal pain, chest pain, angina pectoris, constipation, headache, syncope, diarrhea, pain, chronic pain, sciatica, halitosis, icterus, coughing, vertigo/dizziness, symptoms, dyspepsia, heartburn, gastrointestinal gas, pelvic pain, cold intolerance, joint or joint related complaint

MGI Mouse Phenotypes related to Raynaud Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.23 ACE ADRA2B AGTR1 CD40LG EDN1 HTR3A

Drugs & Therapeutics for Raynaud Disease

Drugs for Raynaud Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
5 Phosphodiesterase Inhibitors Phase 4
6 Respiratory System Agents Phase 4
7 Phosphodiesterase 3 Inhibitors Phase 4
8 Anti-Asthmatic Agents Phase 4
9 Bronchodilator Agents Phase 4
10 Platelet Aggregation Inhibitors Phase 4
11 Fibrinolytic Agents Phase 4
12 Analgesics, Non-Narcotic Phase 4
13 Analgesics Phase 4
14 Cyclooxygenase Inhibitors Phase 4
15 Antipyretics Phase 4
16 Antirheumatic Agents Phase 4
17 Anti-Inflammatory Agents Phase 4
18 Anti-Inflammatory Agents, Non-Steroidal Phase 4
19 Anesthetics Phase 4
20 Anesthetics, Local Phase 4
21 Lidocaine, Prilocaine Drug Combination Phase 4
22 Sodium Channel Blockers Phase 4
23 Anti-Arrhythmia Agents Phase 4
24 Diuretics, Potassium Sparing Phase 4
25 abobotulinumtoxinA Phase 4
26 Cholinergic Agents Phase 4
27 Pharmaceutical Solutions Phase 4
28 Neurotransmitter Agents Phase 4
29 Botulinum Toxins Phase 4
30 Botulinum Toxins, Type A Phase 4
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
Amlodipine Approved Phase 2, Phase 3 88150-42-9 2162
Udenafil Approved, Investigational Phase 2, Phase 3 268203-93-6 6918523
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
Nifedipine Approved Phase 3 21829-25-4 4485
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
Diclofenac Approved, Vet_approved Phase 3 15307-86-5 3033
Tramadol Approved, Investigational Phase 3 27203-92-5 33741
Ephedrine Approved Phase 3 299-42-3 9294
Ondansetron Approved Phase 3 99614-02-5 4595
Pseudoephedrine Approved Phase 3 90-82-4 7028
Atropine Approved, Vet_approved Phase 3 51-55-8, 5908-99-6 174174
Norepinephrine Approved Phase 2, Phase 3 51-41-2 439260
Nitroglycerin Approved, Investigational Phase 3 55-63-0 4510
Iloprost Approved, Investigational Phase 3 78919-13-8 6443959
Terlipressin Approved, Investigational Phase 2, Phase 3 14636-12-5 72081
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
Racepinephrine Approved Phase 2, Phase 3 329-65-7 838
Nitrous oxide Approved, Vet_approved Phase 3 10024-97-2 948

Interventional clinical trials:

(show top 50) (show all 94)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048776 Phase 4 Pletal
2 Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud’s Phenomenon Completed NCT00048763 Phase 4 Pletal
3 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion ("Yuria-Pharm"), in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Pneumonia. Completed NCT03824457 Phase 4 Rheosorbilact®;Ringer lactate
4 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion, in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Peritonitis. Completed NCT03771170 Phase 4 Rheosorbilact®;Ringer lactate
5 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion, in Comparison With Ringer's Lactate, Solution for Infusion, in a Complex Therapy of Sepsis. Completed NCT03764085 Phase 4 Rheosorbilact®;Ringer lactate
6 Evaluation of Effectiveness of Acetylsalicylic Acid on Markers of Vascular Dysfunction in Patients With Systemic Sclerosis Recruiting NCT03558854 Phase 4 Acetylsalicylic acid;Placebo oral capsule
7 Anesthetic Ointment vs Local Injectable Anesthetic in Trans-radial Cardiac Catheterization: The RAOLA Study Recruiting NCT03072394 Phase 4 Local anesthetic;local anaesthetic injection
8 Open-label, Randomized, Controlled, With Blind Assessor, Study to Assess Efficacy and Safety of Rheosorbilact®, Solution for Infusion ("Yuria-Pharm"), in Comparison With Ringer's Lactate,Solution for Infusion, in a Complex Therapy of Burns Recruiting NCT04152096 Phase 4 Rheosorbilact®;Ringer lactate
9 The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon, a Double-Blind Randomized Placebo-Controlled Trial Terminated NCT03639766 Phase 4 AbobotulinumtoxinA
10 A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3 Nitroglycerin;Topical AmphiMatrix
11 A Study of a Topical Formulation of Nitroglycerin, Vascana® (MQX-503), and Matching Vehicle in the Treatment and Prevention of Symptoms Associated With Raynaud's Phenomenon Unknown status NCT00934427 Phase 3 0.9% nitroglycerin in TAM cream;vehicle cream
12 Double-blind, Placebo-controlled Cross-over Study to Investigate the Effects of the Phosphodiesterase 5-inhibitor Vardenafil on Periphery Blood Flow and Clinical Symptoms of Patients With Raynaud's Syndrome Completed NCT01291199 Phase 2, Phase 3 vardenafil;Placebo
13 Comparison of Phosphodiesterase-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon, Double Blind, Randomized, Cross-over Trial Completed NCT01280266 Phase 2, Phase 3 Udenafil or Amlodipine
14 Phase III "in-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon Completed NCT00266669 Phase 3 Topical organogel with nitroglycerin
15 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT00004786 Phase 3 iloprost
16 A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome Completed NCT02165111 Phase 3 Onabotulinumtoxin A;sterile saline solution
17 Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma Completed NCT00626665 Phase 3 Tadalafil
18 Phase III "In-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon Completed NCT00419419 Phase 3 Topical AmphiMatrix with nitroglycerin (MQX-503)
19 Raynaud's Treatment Study (RTS) Completed NCT00000530 Phase 3 nifedipine
20 Efficacy and Safety of "as Required" Sildenafil for Patients With Moderate to Severe Raynaud's Phenomenon (RP) Completed NCT02050360 Phase 2, Phase 3 Sildenafil 40 mg;Sildenafil 80 mg;Placebo
21 A Randomized, Placebo-controlled Trial of St.John's Wort(a Natural Health Product) in the Treatment on Raynaud's Phenomenon Completed NCT00351117 Phase 3 St. John's Wort;Lactose
22 Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud’s Phenomenon Completed NCT00253331 Phase 2, Phase 3 topical organogel with nitroglycerin
23 A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma: A Double Blind, Parallel Group, Multicentric Study Completed NCT01117298 Phase 3 Tadalafil;Placebo
24 Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial Completed NCT01347008 Phase 3 Sildenafil citrate;Placebo (Sugar pill)
25 Efficacy, Tolerability and Biology of a Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon Completed NCT00498615 Phase 3 Fasudil
26 Effects of Addition of Systemic Tramadol or Adjunct Tramadol to Lidocaine Used for Intravenous Regional Anesthesia in Patients Undergoing Hand Surgery Completed NCT02658721 Phase 3 Lidocaine;lidocaine+adjunct tramadol;lidocaine+systemic tramadol;Fentanyl;Atropine;Midazolam;Diclofenac sodium;Ephedrine;Ondansetron
27 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study) Recruiting NCT04040322 Phase 3 Placebo IV infusion;Iloprost Injection, for intravenous use
28 Terlipressin Alone Versus the Standard Therapy With Catecholamines for Hepatic Patients With Septic Shock- Prospective Single Center Randomized Controlled Study. Recruiting NCT03608514 Phase 2, Phase 3 Experimental
29 Topical Nitroglycerin To Prevent Radial Artery Occlusion After Transradial Access: NTP-RAO Trial Recruiting NCT02413268 Phase 3 Nitroglycerin
30 Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Study to Assess Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis Active, not recruiting NCT03717961 Phase 3 BOTOX® solution;Placebo group
31 Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine Terminated NCT02374320 Phase 2, Phase 3 liposomal bupivacaine
32 Safety and Efficacy Study of Pl-vegf165 to Treat Secondary Raynaud's Phenomenon Caused by Systemic Scleroderma Unknown status NCT02356809 Phase 1, Phase 2 Neovasculgen
33 A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma) Completed NCT02228850 Phase 2 Alprostadil
34 A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon Completed NCT01090492 Phase 2 PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791;PF-00489791
35 A 28-Day Randomized, Double-Blind, Placebo-Controlled Clinical Trial and 5-Year Prospective Outcomes Study: A Two-Part Study of BOTOX® Therapy for Ischemic Digits Completed NCT01309802 Phase 2 onabotulinum toxin type-A
36 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT03867097 Phase 2 Placebo IV infusion;Iloprost Injection, for intravenous use
37 A Randomized, Double Blind, Placebo-controlled, Cross-over Pilot Study to Examine the Safety, Tolerability and Pharmacodynamic Profile of Repeat Oral Doses of SLx-2101 Once Daily for up to 14 Days in Subjects With Secondary Raynaud's Disease. Completed NCT00528242 Phase 2 SLx-2101;Placebo
38 Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon Completed NCT00378521 Phase 2 MQX-503
39 Efficacy and Tolerability of Ginkgo Biloba Extract EGb 761® in Patients With Raynaud´s Phenomenon Completed NCT00251238 Phase 2 Ginkgo biloba extract EGb 761
40 Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon Completed NCT00480753 Phase 2 Nitroglycerin
41 Randomized, Placebo-Controlled, Double-Blind, Cross-Over Trial of the Efficacy and Safety of IC351 in Female Patients With Raynaud Phenomenon and Female Sexual Dysfunction Secondary to Systemic Sclerosis Completed NCT00707187 Phase 2 Cialis
42 Single Dose, Double-blind, Placebo-controlled, Single Center, Randomized Cross-over Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetic Properties of BAY63-2521 After Oral Dosing in 20 Patients With Raynaud's Phenomenon (RP) Completed NCT01926847 Phase 2 Riociguat (Adempas, BAY63-2521);Placebo
43 Assessing and Comparing the Effect of Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers. Completed NCT02801305 Phase 2 Diltiazem Gel 2%;Nitroglycerin Ointment 2%;Vaseline
44 A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed NCT02260557 Phase 2 Selexipag;Placebo
45 A Double-blinded Crossover Study of Topical Formulation of Nitroglycerine, Vascana®, Versus Matching Vehicle in the Subjective and Physiologic Responses to Controlled Cold Challenge in Subjects With Raynaud's Phenomenon (RP) Secondary to Connective Tissue Disease Completed NCT02688270 Phase 2 Vascana (0.9% nitroglycerin cream);Vehicle (placebo)
46 A Phase 2, Single-center, Randomised, Double-blind, Placebo-controlled, Cross-over Cold Challenge Study Investigating the Effect of C21 on Cold-induced Vasoconstriction in Subjects With Raynaud's Phenomenon (RP) Secondary to Systemic Sclerosis (SSc) Active, not recruiting NCT04388176 Phase 2 C21;C21;Placebo;Placebo
47 The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis Active, not recruiting NCT02370784 Phase 2 atorvastatin;Placebo
48 Phase IIa Study of the Efficacy of ORM-12471 for Prevention of Cold-induced Vasospasm: a Randomised, Double-blind, Placebo-controlled, Single Centre Crossover Study in Patients With Raynaud's Phenomenon Secondary to Systemic Sclerosis Terminated NCT01315899 Phase 2 ORM-12471 30mg;ORM-12471;placebo
49 A Phase I Trial of the Pharmacodynamic Dose Response to Topical Trinitrate in Patients With Raynaud's Phenomenon Completed NCT00700518 Phase 1 placebo cream;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate;Glyceryl Trinitrate
50 MXQ-503 Applied To The Hand Vs. Nitroglycerin Ointment 2%, USP, Applied To The Chest: A Pharmacokinetic Comparison In Normal Subjects Completed NCT00841594 Phase 1 nitroglycerin 0.9 % (MXQ-503);Nitroglycerin ointment 2%, USP

Search NIH Clinical Center for Raynaud Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Isoxsuprine Hydrochloride
Papaverine Hydrochloride
Prazosin hydrochloride
Tolazoline Hydrochloride

Genetic Tests for Raynaud Disease

Anatomical Context for Raynaud Disease

MalaCards organs/tissues related to Raynaud Disease:

Skin, Lung, Heart, Smooth Muscle, Testes, Endothelial, Spinal Cord

Publications for Raynaud Disease

Articles related to Raynaud Disease:

(show top 50) (show all 1010)
# Title Authors PMID Year
Familial aggregation of primary Raynaud's disease. 61 56
8670329 1996
Raynaud phenomenon and digital ulcers in systemic sclerosis. 42
32099191 2020
Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. 42
31927087 2020
The relationship between Raynaud's phenomenon and Helicobacter pylori. 42
31747762 2019
Renin-angiotensin system mediators and Raynaud's phenomenon. 61 54
17003081 2006
Cardiovascular responses evoked by mild cool stimuli in primary Raynaud's disease: the role of endothelin. 61 54
10334963 1999
Cutaneous responses to endothelin-1 and histamine in patients with vibration white finger. 61 54
9457906 1998
Functional studies in small arteries do not support a primary role for endothelin in the pathogenesis of Raynaud's disease. 61 54
9595516 1998
Highlights on endothelins: a review. 54 61
9441724 1997
Anticentromere autoantibodies. Evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. 61 54
8129780 1994
[New therapeutic possibilities with drugs affecting serotonin receptors]. 61 54
1509427 1992
Arterial palmar arch occlusion in a woman with Raynaud's disease taking oral combined menopausal hormone therapy: A case report. 61
32373479 2020
The Use of Ultrasound Guidance for the Treatment of Raynaud Disease of the Hand With Botulinum Toxin. 61
32356950 2020
Right Ventricular Perforation Presenting as Tingling of the Left Breast. 61
32467814 2020
Alexithymia and emotion regulation in patients with Raynaud's disease. 61
32149407 2020
Rhabdomyolysis as an initial presentation of systemic lupus erythematosus: a case report. 61
31703554 2019
Computed Tomography (CT)-Guided Percutaneous Thoracic Sympathetic Chain Radiofrequency Thermocoagulation for Raynaud Disease. 61
31576813 2019
[Antisynthetase syndromes]. 61
31346706 2019
Immunologic adverse reactions of β-blockers and the skin. 61
31384329 2019
Cyanosis With Dysautonomia Mimics Raynaud Disease. 61
31389817 2019
Primary Raynaud Disease. 61
31135869 2019
Botulinum Toxin Injection for Lower Face and Oral Cavity Raynaud Phenomenon After Mandibulectomy, Free Fibula Reconstruction, and Radiation Therapy. 61
30260839 2019
An Atypical Presentation of Raynaud's Disease. 61
30856621 2019
A Literature Based Discovery Visualization System with Hierarchical Clustering and Linking Set Associations. 61
31259013 2019
Acupuncture Point "Hegu" (LI4) Is Close to the Vascular Branch from the Superficial Branch of the Radial Nerve. 61
31341499 2019
Systemic Sclerosis and Serum Content of Transforming Growth Factor. 61
30758773 2019
The importance of perfusion index monitoring in evaluating the efficacy of stellate ganglion blockage treatment in Raynaud's disease. 61
29350104 2018
New onset acute pulmonary edema after methylergonovine given during cesarean delivery of a patient with undiagnosed Raynaud's disease. 61
30392649 2018
Anatomical Variation of the Radial Artery Associated With Clinically Significant Ischemia. 61
29602651 2018
Vascular branches from cutaneous nerve of the forearm and hand: Application to better understanding raynaud's disease. 61
28960445 2018
Effects of Endoscopic Thoracic Sympathectomy on Raynaud's Disease. 61
29327980 2018
[Quality of life of patients with Raynaud's disease]. 61
29658285 2018
Agreement between ccNexfin CO-trek cardiac output and intermittent cold-bolus pulmonary thermodilution in a prospective multicenter study. 61
29239149 2018
[Etiological profile of secondary Raynaud's phenomenon in an internal medicine department. About 121 patients]. 61
29425538 2018
Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases. 61
29044769 2018
Hyperbaric oxygen therapy for digital ulcers due to Raynaud's disease. 61
30397635 2018
Calcinosis Cutis: WOC Nurse Management. 61
29300294 2018
Surgical Interventions for Organ and Limb Ischemia Associated With Primary and Secondary Antiphospholipid Antibody Syndrome With Arterial Involvement. 61
28920529 2017
Classification of Japanese patients with mild/early systemic sclerosis (SSc) by the 2013 ACR/EULAR classification criteria for SSc. 61
27830961 2017
Autoantibody to scaffold attachment factor B (SAFB): A novel connective tissue disease-related autoantibody associated with interstitial lung disease. 61
27682649 2017
Acute Vision Loss Following Endoscopic Sinus Surgery. 61
28286685 2017
[Hematopoietic stem cells transplant in patients with common variable immunodeficiency. Is a therapeutic option?] 61
28188718 2017
Comparison of Transradial vs Transfemoral Access for Aortoiliac and Femoropopliteal Interventions: A Single-Center Experience. 61
27558461 2016
Thoracic sympathectomy for upper extremity ischemia. 61
27175977 2016
Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers. 61
27465880 2016
Endoscopic thoracic sympathectomy for upper limb ischemia. A 16 year follow-up in a single center. 61
25900032 2016
Raynaud's Syndrome: a neglected disease. 61
25673314 2016
A Review of Raynaud's Disease. 61
27311222 2016
Severe Primary Raynaud's Disease Treated with Rituximab. 61
27651971 2016
Synergistic Effect of Ferulic Acid and Z-Ligustilide, Major Components of A. sinensis, on Regulating Cold-Sensing Protein TRPM8 and TPRA1 In Vitro. 61
27413384 2016

Variations for Raynaud Disease

Expression for Raynaud Disease

Search GEO for disease gene expression data for Raynaud Disease.

Pathways for Raynaud Disease

Pathways related to Raynaud Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
2 10.64 EDN1 AGTR1 ACE

GO Terms for Raynaud Disease

Biological processes related to Raynaud Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.76 EDN1 CALCA ADRA2C ADRA2B
2 inflammatory response GO:0006954 9.72 IL1R1 CRP CD40LG CALCA AGTR1
3 platelet activation GO:0030168 9.67 CD40LG ADRA2C ADRA2B
4 regulation of blood pressure GO:0008217 9.58 EDN1 CALCA ACE
5 adrenergic receptor signaling pathway GO:0071875 9.48 ADRA2C ADRA2B
6 negative regulation of norepinephrine secretion GO:0010700 9.43 ADRA2C ADRA2B
7 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.37 AGTR1 ACE
8 receptor transactivation GO:0035624 9.26 ADRA2C ADRA2B
9 negative regulation of epinephrine secretion GO:0032811 9.16 ADRA2C ADRA2B
10 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.13 EDN1 CALCA AGTR1
11 regulation of vasoconstriction GO:0019229 9.02 EDN1 AGTR1 ADRA2C ADRA2B ACE

Molecular functions related to Raynaud Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 epinephrine binding GO:0051379 9.16 ADRA2C ADRA2B
2 alpha2-adrenergic receptor activity GO:0004938 8.96 ADRA2C ADRA2B
3 bradykinin receptor binding GO:0031711 8.62 AGTR1 ACE

Sources for Raynaud Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....